Since the approval of the first immune checkpoint inhibitor (ICI), ipilimumab (anti-CTLA-4), in 2011, additional ICIs have emerged as a significant therapeutic approach to reinvigorate anti-tumor responses and eliminate malignant cells. This evidence concerns the gene CTLA4 and neoplasm.